P物质及其速激肽NK1受体：帕金森病的新型神经保护靶点。 - Suppr

Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease.

作者信息

Thornton Emma, Vink Robert

机构信息

School of Medical Sciences, University of Adelaide, Adelaide, Australia; Division of Health Sciences, University of South Australia, Adelaide, Australia.

出版信息

Neural Regen Res. 2015 Sep;10(9):1403-5. doi: 10.4103/1673-5374.165505.

DOI:10.4103/1673-5374.165505

PMID:26604896

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4625501/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bfc/4625501/39f78d83fe03/NRR-10-1403-g001.jpg

相似文献

Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease.

Neural Regen Res. 2015 Sep;10(9):1403-5. doi: 10.4103/1673-5374.165505.

Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykinin NK1 receptor antagonist.

Eur J Pharmacol. 1997 May 1;325(2-3):253-61. doi: 10.1016/s0014-2999(97)00122-2.

Temperature and agonist dependency of tachykinin NK1 receptor antagonist potencies in rat isolated superior cervical ganglion.

Eur J Pharmacol. 1995 Dec 27;294(1):163-71. doi: 10.1016/0014-2999(95)00521-8.

Substance P-induced contractions of the guinea-pig proximal colon through stimulation of post-junctional tachykinin NK1 receptors.

Eur J Pharmacol. 1993 Nov 30;250(1):181-3. doi: 10.1016/0014-2999(93)90640-4.

Chromodacryorrhea and repetitive hind paw tapping: models of peripheral and central tachykinin NK1 receptor activation in gerbils.

Eur J Pharmacol. 1994 Mar 3;253(3):245-52. doi: 10.1016/0014-2999(94)90198-8.

Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice.

Eur J Pharmacol. 1996 Sep 5;311(1):7-14. doi: 10.1016/0014-2999(96)00390-1.

The tachykinin NK1 receptor in the brain: pharmacology and putative functions.

Eur J Pharmacol. 1999 Jun 30;375(1-3):51-60. doi: 10.1016/s0014-2999(99)00259-9.

Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonist.

Eur J Pharmacol. 1998 Jan 12;341(2-3):201-9. doi: 10.1016/s0014-2999(97)01453-2.

SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.

J Pharmacol Exp Ther. 2002 Dec;303(3):1171-9. doi: 10.1124/jpet.102.040162.

Tachykinin NK1 receptor subtypes in the rat urinary bladder.

Br J Pharmacol. 1994 Mar;111(3):739-46. doi: 10.1111/j.1476-5381.1994.tb14800.x.

引用本文的文献

Construction and Identification of Inflammation-Related TF-mRNA-miRNA Coexpression Network and Immune Infiltration in Parkinson's Disease.

Parkinsons Dis. 2025 May 7;2025:2323585. doi: 10.1155/padi/2323585. eCollection 2025.

The association between migraine and Parkinson's disease: a nationwide cohort study.

Epidemiol Health. 2024;46:e2024010. doi: 10.4178/epih.e2024010. Epub 2023 Dec 18.

Therapeutic Targeting of Krüppel-Like Factor 4 and Its Pharmacological Potential in Parkinson's Disease: a Comprehensive Review.

Mol Neurobiol. 2024 Jun;61(6):3596-3606. doi: 10.1007/s12035-023-03800-2. Epub 2023 Nov 24.

A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease.

Front Neurosci. 2022 Apr 19;16:797127. doi: 10.3389/fnins.2022.797127. eCollection 2022.

N-acetyl-L-tryptophan attenuates hepatic ischemia-reperfusion injury via regulating TLR4/NLRP3 signaling pathway in rats.

PeerJ. 2021 Aug 10;9:e11909. doi: 10.7717/peerj.11909. eCollection 2021.

Subclinical Lipopolysaccharide from Enteritidis Induces Dysregulation of Bioactive Substances from Selected Brain Sections and Glands of Neuroendocrine Axes.

Toxins (Basel). 2019 Feb 2;11(2):91. doi: 10.3390/toxins11020091.

Neuropeptides and Microglial Activation in Inflammation, Pain, and Neurodegenerative Diseases.

Mediators Inflamm. 2017;2017:5048616. doi: 10.1155/2017/5048616. Epub 2017 Jan 5.

Substance P and Antagonists of the Neurokinin-1 Receptor in Neuroinflammation Associated with Infectious and Neurodegenerative Diseases of the Central Nervous System.

J Neurol Neuromedicine. 2016;1(2):29-36. doi: 10.29245/2572.942x/2016/2.1020.

本文引用的文献

Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.

Exp Neurol. 2015 Sep;271:168-74. doi: 10.1016/j.expneurol.2015.05.007. Epub 2015 May 20.

The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.

Parkinsonism Relat Disord. 2014 May;20(5):508-13. doi: 10.1016/j.parkreldis.2014.02.008. Epub 2014 Feb 20.

Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease.

J Neuroinflammation. 2012 Aug 8;9:188. doi: 10.1186/1742-2094-9-188.

Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease.

PLoS One. 2012;7(4):e34138. doi: 10.1371/journal.pone.0034138. Epub 2012 Apr 2.

A substance P mediated pathway contributes to 6-hydroxydopamine induced cell death.

Neurosci Lett. 2010 Aug 30;481(1):64-7. doi: 10.1016/j.neulet.2010.06.057. Epub 2010 Jun 25.

Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease.

J Clin Invest. 2009 Jan;119(1):182-92. doi: 10.1172/JCI36470. Epub 2008 Dec 22.

Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats.

Neuropharmacology. 2007 Dec;53(7):832-41. doi: 10.1016/j.neuropharm.2007.08.014. Epub 2007 Aug 25.

Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons.

J Neurochem. 2007 Jun;101(6):1567-82. doi: 10.1111/j.1471-4159.2007.04567.x. Epub 2007 Apr 16.

Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.

J Neurosci. 2006 Sep 13;26(37):9448-61. doi: 10.1523/JNEUROSCI.0944-06.2006.

The blood-brain barrier/neurovascular unit in health and disease.

Pharmacol Rev. 2005 Jun;57(2):173-85. doi: 10.1124/pr.57.2.4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献